Spots Global Cancer Trial Database for RX-5902 Treatment of Subjects With Triple Negative Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: RX-5902 Treatment of Subjects With Triple Negative Breast Cancer

Official Title: A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors

Study ID: NCT02003092

Conditions

Solid Tumor

Triple Negative Breast Cancer

Interventions

RX-5902

Study Description

Brief Summary: The purpose of this Phase 2 portion of the study is to use the dose and schedule of RX-5902 identified in the phase 1 to treat subjects with triple negative breast cancer.

Detailed Description: In this dose-finding, open-label, single-agent study of RX-5902, subjects will be treated for up to 6 cycles of therapy. RX-5902 will be administered orally daily for 3 weeks followed by 1 week of rest in each cycle. All subjects will be followed for at least 30 days after the last dose of study agent for safety.